Sign up for Table of Contents Alerts.
Email this page
Print this page
Research Paper
MAGED4 – Expression in Renal Cell Carcinoma and Identification of an HLA-A*25-Restricted MHC Class I Ligand from Solid Tumor Tissue
Björn F. Krämer, Oliver Schoor, Tobias Krüger, Christian Reichle, Margret Müller, Toni Weinschenk, Jörg Hennenlotter, Arnulf Stenzl, Hans-Georg Rammensee and Stefan Stevanovic
volume 4 | issue 9
september 2005Pages: 943-948
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
MAGE derived HLA ligands have repeatedly been shown to elicit T-cell responses against tumor cells. In renal cell carcinoma (RCC), however, only few T-cell epitopes from cancer testis antigens have been described. To identify potential candidates, we applied a combined approach of microarray/qPCR expression analysis and sequencing of HLA ligands from RCC by mass spectrometry. We analyzed the expression of 21 MAGE genes in 10 RCC samples and 2 glioblastoma samples and could identify the first MHC class I ligand NIGDEALIGRW from MAGED4 presented by HLA-A*25 on RCC solid tumor tissue. MAGED4 was expressed in 30% of RCC and both glioblastoma samples. Among the other MAGE family members only MAGEB2 and -C1 and the broadly expressed MAGED1, -D2, -F1, and -H1 were expressed in RCC. Ligands from MAGED4 could thus be interesting tumor-associated antigens in a subset of RCC, even though the identified ligand is presented by a rather rare allele.
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.